Biphasic Positive Airway Pressure Ventilation Versus Flow-Controlled Ventilation in Burn Patients: A Monocentric, Randomized Controlled, Parallel Group Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Mechanical power
研究概览
简要总结
The goal of this clinical trial is to learn if the new ventilation mode flow-controlled ventilation (FCV) is a more protective mode of ventilation for adult patients after severe burn injury. The main question it aims to answer is:
Does FCV reduce the mechanical power (a key determinant of ventilator-induced lung injury) compared to conventional pressure-controlled ventilation (PCV) during ventilation of patients with burn injury?
Researchers will compare FCV with PCV for up to 70 hours of ventilation to see if the mechanical power is reduced during ventilation of participants being in need of ventilation after severe burn injury.
Ventilation of participants will be controlled by either FCV or PCV. Group-specific ventilation will have the following characteristics:
- FCV: Control of airway flows during inspiration and expiration, use of individualized lower and upper airway pressures and no fixed values for the volumes being inspired and expired (tidal volumes)
- PCV: No control of airway flows during expiration, use of individualized lower airway pressures and upper airway pressures for a fixed tidal volume during each breath (6-8 ml/kg ideal body weight)
In total, at least 24 participants in need of ventilation after severe burn injury will be ventilated either with FCV (12 participants) or PCV (12 participants) for up to 70 hours.
During ventilation mechanical power is computed according to certain ventilation parameters. Additionally, we evaluate organ functions of the cardiovascular systems, the lungs and other organs during and after the group-specific ventilation.
详细描述
Invasive ventilation can cause ventilator-induced lung injury. There is growing evidence that high mechanical power during (prolonged) controlled ventilation is associated with ventilator-induced lung injury and pulmonary complications.
Large animal model and perioperative clinical trial data have shown that the individualized application of the flow-controlled ventilation (FCV) mode can reduce mechanical power compared to conventional pressure-controlled ventilation (PCV).
Burn patients with or without inhalational injury are at high risk of pulmonary complications like pneumonias or the acute respiratory distress syndrome due to the hyperinflammatory state and also the intensive care treatment after a burn injury. If these patients need mechanical ventilation, this might aggravate lung injury.
With the study BIFLOWBURN we want to test the hypothesis that the mechanical power during controlled ventilation of burn patients is reduced with the individualized application of FCV compared to conventional PCV via Biphasic Positive Airway Pressure (BIPAP) ventilation.
BIFLOWBURN is a single-center, randomized, parallel-group trial with two intervention arms:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
盲法说明
Due to different ventilators during the interventions, outcome assessors can only be blinded after intervention withdrawal. Participants are blinded throughout the study.
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body weight ≥ 40 kg
- •Invasive ventilation time ≤ 24 hours before admission to the burn ICU or indication for intubation and invasive ventilation within 48 hours after admission to the burn ICU
- •Estimated (further) invasive ventilation time ≥ 24 hours
- •Intervention start within 48 hours after admission to the burn ICU
- •Establishment of a central venous line and invasive blood pressure monitoring as part of the intensive care therapy before the intervention start
- •Signed informed consent from the participant, legal guardian, next of kin in incompetent patients, or an intensivist in charge and independent from the Trial Management Committee in incompetent patients without a representative of the patients will
排除标准
- •Participation in another interventional trial
- •Duration of invasive ventilation > 24 hours at the time point of admission to the burn ICU
- •Estimated (further) invasive ventilation time < 24 hours
- •Patients being treated in the burn ICU for (suspected) severe skin reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- •Lack of consent from the participant, legal guardian, next of kin, or intensivist in charge to participate in the study
研究组 & 干预措施
Flow-Controlled Ventilation
Individualized flow-controlled ventilation (FCV) with a compliance-guided positive end-expiratory pressure (PEEP), a compliance-guided driving pressure (ΔP) resulting in a liberal tidal volume, and adjustment of airway flows and respiratory rates being required for normocapnia.
干预措施: Individualized flow-controlled ventilation strategy (Other)
Pressure-Controlled Ventilation via Biphasic Positive Airway Pressure Ventilation
Conventional pressure-controlled ventilation via application of Biphasic Positive Airway Pressure (BIPAP) ventilation with a compliance-guided positive end-expiratory pressure (PEEP), a driving pressure (ΔP) for a tidal volume of 6-8 ml/kg predicted body weight, and adjustment of respiratory rates being required for normocapnia but no adjustment/control of airway flows.
干预措施: Pressure-controlled ventilation strategy via the application of Biphasic Positive Airway Pressure ventilation (Other)
结局指标
主要结局
Mechanical power
时间窗: Mechanical power will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.
We will compute mechanical power in joules per minute (J/min) hourly according to the surrogate formulae \[Minute ventilation \* (Peak airway pressure + PEEP + Inspiratory flow/6)\]/20 for FCV and 0.098 \* respiratory rate \* tidal volume \* \[PEEP + ΔP\] for PCV/BIPAP
次要结局
- Mortality(Participants will be followed-up for 6 months after the interventions.)
- Minute volume(Minute volumes will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Dynamic compliance(Dynamic compliances will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Dissipated energy/power(The dissipated energy/power will be assessed at least hourly/continously during up to 70 hours of controlled, group-specific ventilation.)
- Respiratory rate(Respiratory rates will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Tidal volume(Tidal volumes will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Airway pressures(Airway pressures will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Airway resistance(Airway resistances will be assessed hourly during up to 70 hours of controlled, group-specific ventilation.)
- Oxygenation indices(Oxygenation indices will be assessed every 4-8 hours with arterial blood gas analyses during up to 70 hours of controlled, group-specific ventilation.)
- Pulmonary complications(Pulmonary complications will be assessed within the first ten days after randomization.)
- Extra-pulmonary complications(Extra-pulmonary complications will be assessed within the first ten days after randomization.)
- Sequential Organ Failure Assessment (SOFA) Score(The Sequential Organ Failure Assessment (SOFA) Score will be assessed daily within the first ten days after randomization.)
- Lung Injury Score (Murray)(The Lung Injury Score will be assessed daily within the first ten days after randomization.)
- Acute Physiology and Chronic Health Evaluation (APACHE) Score(The Acute Physiology and Chronic Health Evaluation (APACHE) Score will be assessed daily within the first ten days after randomization.)
- Duration of invasive ventilation(Participants will be followed-up on length of invasive ventilation for 6 months after the interventions.)
- Length of stay(Participants will be followed-up for 6 months after the interventions.)
研究者
Simon Becker
Jun.-Prof. Dr. med. Simon Becker, M.D.
University Hospital Bergmannsheil Bochum